EGFR and non-small cell lung carcinoma: While a small phase II trial investigating combination therapy with gefitinib (EGFR inhibitor) + bevacizumab for EGFR-mutant NSCLC demonstrated inferior PFS compared to gefitinib alone [46], Saito et al. demonstrated that bevacizumab + erlotinib improved PFS on interim analysis compared to erlotinib alone [47].